|
Pharmokineticks:
Lansodol is an antisecretory drug wich doesn’t exhibit anticholinergic or histamine H2- receptor antagonist properties but suppress gastric acid secretion. by specific inhibition of the ( H+ , K+ ) - ATPase enzyme system at the secretory surface of the gastric parietal cell and this enzyme system is regarded as the acid pump within the parietal cell . so it blocks the final step of acid production and inhibit both basal and stimulated gastric acid secretion .
Absorption of lansoprazol begins only after the granules leaves the stomach . Absorption is rapid with mean peak plasma after 1.7 hours , with bioavailability over 80% . Its plasma half life is
1.5 ± 1 hour . It is 97% bound to plasma proteins . It is metabolized in the liver (hydroxylated sulfinyl and sulfone derivatives) one third is excreted in the urine and two thirds in the feces. |
|
Drugs and Interaction:
Sucralfate reduces the bioavailability of lansoprazol therefore lansoprazole should be taken 30minutes before sucralfate.
It may interfere with the absorption of drugs where gastric PH is an important determinant of bioavailability ( eg. Ketoconazole , ampicilline esters , iron salts , digoxin )
creatinine , alkaline phosphatase , globulins , GGTP , glucocorticoids , LDH , gastrin levels .
It may give ab normal : WBC , AG ratio , RBC , bilirubinemia , eosinophilia , hyperlipemia , electrolytes , cholestrol and platelets |